Skip to main content

Table 2 Independent factors of progression-free survival and overall survival from multivariate analysis of the training cohort

From: Enhancement of the International prognostic index with β2-microglobulin, platelet count and red blood cell distribution width: a new prognostic model for diffuse large B-cell lymphoma in the rituximab era

Characteristic

Progression-free survival

Overall survival

Score

HR (95%CI)

P

HR (95%CI)

P

IPI risk group

 Low (0–1)

Reference

 

Reference

 

0

 Low-intermediate (2)

2.003 (1.411–2.845)

< 0.001

2.401 (1.593–3.618)

< 0.001

2

 High-intermediate (3)

2.922 (2.053–4.159)

< 0.001

3.346 (2.211–5.064)

< 0.001

3

 High (4–5)

4.073 (2.684–6.182)

< 0.001

5.341 (3.301–8.644)

< 0.001

5

β2-microglobulin level

 Normal

Reference

 

Reference

 

0

 Elevated

1.543 (1.181–2.016)

0.001

1.411 (1.040–1.913)

0.027

1

PLT (×109/L)

  ≥ 157

Reference

 

Reference

 

0

  < 157

1.433 (1.010–2.034)

0.044

1.548 (1.038–2.308)

0.032

1

RDW (%)

  < 14.5

Reference

 

Reference

 

0

  ≥ 14.5

1.438 (1.022–2.023)

0.037

1.758 (1.214–2.547)

0.003

1

  1. Abbreviations: IPI International Prognostic Index, HR Hazard ratio, PLT Platelet, RDW Red blood cell distribution width
  2. This multivariate analysis included the grouped IPI but excluded individual IPI factors